Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Change in Accured Expenses (2016 - 2025)

BioCorRx's Change in Accured Expenses history spans 12 years, with the latest figure at $868743.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 114.75% year-over-year to $868743.0; the TTM value through Sep 2025 reached $1.8 million, up 9.62%, while the annual FY2024 figure was $1.4 million, 79.57% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $868743.0 at BioCorRx, down from $934022.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $934022.0 in Q2 2025 and bottomed at -$402386.0 in Q2 2021.
  • The 5-year median for Change in Accured Expenses is $262444.0 (2022), against an average of $294793.5.
  • The largest annual shift saw Change in Accured Expenses soared 527.58% in 2023 before it plummeted 102.97% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $307991.0 in 2021, then plummeted by 46.83% to $163767.0 in 2022, then grew by 25.55% to $205612.0 in 2023, then tumbled by 102.97% to -$6106.0 in 2024, then surged by 14327.69% to $868743.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Change in Accured Expenses are $868743.0 (Q3 2025), $934022.0 (Q2 2025), and $16333.0 (Q1 2025).